統合失調感情障害の世界市場レポート 2025年

統合失調感情障害市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.1％で94億7,000万米ドルに成長します。予測期間における成長の背景には、精神疾患の有病率の上昇、精神科治療薬開発への投資の増加、精神疾患に対する一般市民の意識の高まり、新興国市場におけるヘルスケアインフラの拡大、個別化医療アプローチの台頭などがあります。主な動向としては、非定型抗精神病薬の開発、デジタルヘルスプラットフォームの発展、長時間作用型注射薬の革新、診断ツールの改善、治療管理におけるAIの統合、精神療法技術の強化などが挙げられます。

神経疾患の有病率の増加は、統合失調感情障害市場の拡大を促進すると予想されます。神経疾患は、脳、脊髄、神経を含む神経系に影響を及ぼし、さまざまな認知、運動、感覚の機能障害を引き起こします。神経障害の増加要因には、遺伝子変異、感染症、外傷、環境毒素、自己免疫反応、変性過程などがあります。これらの疾患の有病率の増加は、共通の生物学的メカニズム、診断能力の進歩、意識の高まりにより、統合失調感情障害診断の増加をもたらしています。例えば、2023年4月、米国の医学研究機関である国立医学図書館は、約670万人の米国人がアルツハイマー病を患っていると報告し、2060年までに1,380万人に増加すると予測しています。その結果、神経疾患の罹患率の増加が統合失調感情障害市場の成長を後押ししています。

統合失調感情障害市場の主要企業は、治療効果を高め、患者のアドヒアランスを改善し、投与回数を減らすために、徐放性注射懸濁製剤などの革新的な製剤の開発に注力しています。徐放性注射懸濁製剤は、有効成分を長期間にわたって徐々に放出する製剤であり、従来の即時放出型薬剤と比較して投与回数を減らすことができます。例えば、2024年7月、中国の製薬会社であるLuye Pharma Group Ltd.は、米国食品医薬品局（FDA）から、統合失調症および統合失調感情障害の治療薬としてERZOFRI（パルミチン酸パリペリドン）徐放性注射用懸濁液の承認を取得しました。この長時間作用型の注射剤は、体内の薬物レベルを一定に保つため、投与回数を減らし、患者の服薬アドヒアランスを向上させ、再発のリスクを低下させます。経口薬に比べ注射回数が少ないため利便性が高く、慢性的な精神疾患を抱える患者のQOLを大幅に向上させる。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界統合失調感情障害 PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の統合失調感情障害市場：成長率分析
• 世界の統合失調感情障害市場の実績：規模と成長, 2019-2024
• 世界の統合失調感情障害市場の予測：規模と成長, 2024-2029, 2034F
• 世界統合失調感情障害総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の統合失調感情障害市場薬物によって、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗精神病薬
• 気分安定剤
• 抗うつ薬
• 抗けいれん薬
• 世界の統合失調感情障害市場原因別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 遺伝的要因
• 環境要因
• 化学的要因
• 世界の統合失調感情障害市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• その他のエンドユーザー
• 世界の統合失調感情障害市場抗精神病薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 非定型抗精神病薬
• 定型抗精神病薬
• 世界の統合失調感情障害市場気分安定剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• リチウム
• バルプロ酸
• ラモトリギン
• カルバマゼピン
• 世界の統合失調感情障害市場抗うつ薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 選択的セロトニン再取り込み阻害薬（SSRI）
• セロトニン・ノルエピネフリン再取り込み阻害剤（SNRI）
• 三環系抗うつ薬（TCA）
• モノアミン酸化酵素阻害剤（MAOI）
• 世界の統合失調感情障害市場抗てんかん薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ラモトリギン
• バルプロ酸
• トピラマート
• レベチラセタム

第7章 地域別・国別分析

• 世界の統合失調感情障害市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の統合失調感情障害市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 統合失調感情障害市場：競合情勢
• 統合失調感情障害市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Boehringer Ingelheim International GmbH
• Zydus Lifesciences Limited
• Neurocrine Biosciences Inc.
• Alkermes Inc.
• Luye Pharma Group Ltd.
• Merz Pharma GmbH & Co. KGaA
• Acadia Pharmaceuticals Inc.
• Intra-Cellular Therapies Inc.
• Cerevel Therapeutics Inc.
• Avanir Pharmaceuticals Inc.
• Otsuka Pharmaceutical Co. Ltd.
• Reviva Pharmaceuticals Inc.
• Zogenix Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 統合失調感情障害市場2029：新たな機会を提供する国
• 統合失調感情障害市場2029：新たな機会を提供するセグメント
• 統合失調感情障害市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Schizoaffective disorder is a chronic mental illness that combines symptoms of schizophrenia, such as delusions and hallucinations, with mood disorder symptoms, including depressive or manic episodes. Managing this condition requires a multidisciplinary approach that integrates both therapeutic and pharmaceutical interventions to address its complex nature.

The primary medications used to treat schizoaffective disorder include antipsychotic medications, mood stabilizers, antidepressants, and anticonvulsants. Antipsychotic medications help control psychotic symptoms such as hallucinations, delusions, and disorganized thinking. The disorder can be influenced by genetic, environmental, and chemical factors. Treatment is provided in various healthcare settings, including hospitals, clinics, and other medical facilities.

The schizoaffective disorder market research report is one of a series of new reports from The Business Research Company that provides schizoaffective disorder market statistics, including the schizoaffective disorder industry's global market size, regional shares, competitors with a schizoaffective disorder market share, detailed schizoaffective disorder market segments, market trends and opportunities, and any further data you may need to thrive in the schizoaffective disorder industry. This schizoaffective disorder market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The schizoaffective disorder market size has grown strongly in recent years. It will grow from $7.36 billion in 2024 to $7.77 billion in 2025 at a compound annual growth rate (CAGR) of 5.5%. The growth during the historic period can be attributed to increased awareness of mental health disorders, improved diagnostic criteria, higher healthcare funding, expanded access to mental health services, a rising prevalence of mental health conditions, and greater availability of treatments for psychiatric illnesses.

The schizoaffective disorder market size is expected to see strong growth in the next few years. It will grow to $9.47 billion in 2029 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to the rising prevalence of mental health conditions, increased investment in psychiatric drug development, growing public awareness of mental illnesses, expanding healthcare infrastructure in emerging markets, and the rise of personalized medicine approaches. Key trends include the development of atypical antipsychotics, advancements in digital health platforms, innovation in long-acting injectable medications, improved diagnostic tools, the integration of AI in therapy management, and enhancements in psychotherapeutic techniques.

The increasing prevalence of neurological disorders is expected to drive the expansion of the schizoaffective disorder market. Neurological disorders affect the nervous system, including the brain, spinal cord, and nerves, leading to various cognitive, motor, and sensory dysfunctions. Factors contributing to the rise in neurological disorders include genetic mutations, infections, traumatic injuries, environmental toxins, autoimmune responses, and degenerative processes. The growing prevalence of these conditions has led to an increase in schizoaffective disorder diagnoses due to shared biological mechanisms, advancements in diagnostic capabilities, and heightened awareness. For example, in April 2023, the National Library of Medicine, a US-based medical research institution, reported that approximately 6.7 million Americans were living with Alzheimer's disease, with projections indicating an increase to 13.8 million by 2060. As a result, the rising incidence of neurological disorders is fueling the growth of the schizoaffective disorder market.

Leading companies in the schizoaffective disorder market are focusing on the development of innovative drug formulations, such as extended-release injectable suspension drugs, to enhance treatment efficacy, improve patient adherence, and reduce dosing frequency. Extended-release injectable suspension drugs are formulated to release their active ingredients gradually over an extended period, allowing for less frequent dosing compared to traditional immediate-release medications. For instance, in July 2024, Luye Pharma Group Ltd., a China-based pharmaceutical company, received approval from the US Food and Drug Administration (FDA) for ERZOFRI (paliperidone palmitate) extended-release injectable suspension for the treatment of schizophrenia and schizoaffective disorder. This long-acting injectable formulation ensures a consistent medication level in the body, reducing the frequency of administration, improving patient adherence, and lowering the risk of relapse. The convenience of fewer injections compared to oral medications significantly enhances the quality of life for individuals with chronic mental health conditions.

In March 2024, Bristol Myers Squibb, a US-based biopharmaceutical company, acquired Karuna Therapeutics Inc. for an undisclosed amount. This acquisition aims to strengthen Bristol Myers Squibb's neuroscience portfolio by incorporating Karuna Therapeutics' innovative schizophrenia treatment, KarXT, along with its early-stage pipeline. Karuna Therapeutics Inc., a US-based biopharmaceutical company, specializes in developing treatments for psychiatric and neurological conditions, including schizophrenia.

Major players in the schizoaffective disorder market are Pfizer Inc., Johnson & Johnson, Bristol Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Zydus Lifesciences Limited, Neurocrine Biosciences Inc., Alkermes Inc., Luye Pharma Group Ltd., Merz Pharma GmbH & Co. KGaA, Acadia Pharmaceuticals Inc., Intra-Cellular Therapies Inc., Cerevel Therapeutics Inc., Avanir Pharmaceuticals Inc., Otsuka Pharmaceutical Co. Ltd., Reviva Pharmaceuticals Inc., Zogenix Inc., Sunovion Pharmaceuticals Inc., Newron Pharmaceuticals S.p.A., Sage Therapeutics Inc., Lyndra Therapeutics Inc., BioXcel Therapeutics Inc.

North America was the largest region in the schizoaffective disorder market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in schizoaffective disorder report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the schizoaffective disorder market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The schizoaffective disorder market consists of revenues earned by entities by providing services such as clinical interviews, psychological assessments, cognitive-behavioral therapy (CBT), interpersonal therapy, and vocational rehabilitation. The market value includes the value of related goods sold by the service provider or included within the service offering. The schizoaffective disorder market includes sales of drugs such as risperidone, olanzapine, lithium and valproate, and fluoxetine or sertraline. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Schizoaffective Disorder Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on schizoaffective disorder market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for schizoaffective disorder ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The schizoaffective disorder market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drugs: Antipsychotic Medication; Mood Stabilizers; Antidepressant Medication; Anticonvulsants
• 2) By Causes: Genetic Factors; Environmental Factors; Chemical Factors
• 3) By End User: Hospitals; Clinics; Other End User
• Subsegments:
• 1) By Antipsychotic Medication: Atypical Antipsychotics; Typical Antipsychotics
• 2) By Mood Stabilizers: Lithium; Valproate; Lamotrigine; Carbamazepine
• 3) By Antidepressant Medication: Selective Serotonin Reuptake Inhibitors (SSRIs); Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs); Tricyclic Antidepressants (TCAs); Monoamine Oxidase Inhibitors (MAOIs)
• 4) By Anticonvulsants: Lamotrigine; Valproate; Topiramate; Levetiracetam
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Bristol Myers Squibb Company; AstraZeneca PLC; Abbott Laboratories
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Schizoaffective Disorder Market Characteristics

3. Schizoaffective Disorder Market Trends And Strategies

4. Schizoaffective Disorder Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Schizoaffective Disorder Growth Analysis And Strategic Analysis Framework

• 5.1. Global Schizoaffective Disorder PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Schizoaffective Disorder Market Growth Rate Analysis
• 5.4. Global Schizoaffective Disorder Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Schizoaffective Disorder Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Schizoaffective Disorder Total Addressable Market (TAM)

6. Schizoaffective Disorder Market Segmentation

• 6.1. Global Schizoaffective Disorder Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antipsychotic Medication
• Mood Stabilizers
• Antidepressant Medication
• Anticonvulsants
• 6.2. Global Schizoaffective Disorder Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Genetic Factors
• Environmental Factors
• Chemical Factors
• 6.3. Global Schizoaffective Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Other End User
• 6.4. Global Schizoaffective Disorder Market, Sub-Segmentation Of Antipsychotic Medication, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Atypical Antipsychotics
• Typical Antipsychotics
• 6.5. Global Schizoaffective Disorder Market, Sub-Segmentation Of Mood Stabilizers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lithium
• Valproate
• Lamotrigine
• Carbamazepine
• 6.6. Global Schizoaffective Disorder Market, Sub-Segmentation Of Antidepressant Medication, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Selective Serotonin Reuptake Inhibitors (SSRIs)
• Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
• Tricyclic Antidepressants (TCAs)
• Monoamine Oxidase Inhibitors (MAOIs)
• 6.7. Global Schizoaffective Disorder Market, Sub-Segmentation Of Anticonvulsants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lamotrigine
• Valproate
• Topiramate
• Levetiracetam

7. Schizoaffective Disorder Market Regional And Country Analysis

• 7.1. Global Schizoaffective Disorder Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Schizoaffective Disorder Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Schizoaffective Disorder Market

• 8.1. Asia-Pacific Schizoaffective Disorder Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Schizoaffective Disorder Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Schizoaffective Disorder Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Schizoaffective Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Schizoaffective Disorder Market

• 9.1. China Schizoaffective Disorder Market Overview
• 9.2. China Schizoaffective Disorder Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Schizoaffective Disorder Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Schizoaffective Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Schizoaffective Disorder Market

• 10.1. India Schizoaffective Disorder Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Schizoaffective Disorder Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Schizoaffective Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Schizoaffective Disorder Market

• 11.1. Japan Schizoaffective Disorder Market Overview
• 11.2. Japan Schizoaffective Disorder Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Schizoaffective Disorder Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Schizoaffective Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Schizoaffective Disorder Market

• 12.1. Australia Schizoaffective Disorder Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Schizoaffective Disorder Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Schizoaffective Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Schizoaffective Disorder Market

• 13.1. Indonesia Schizoaffective Disorder Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Schizoaffective Disorder Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Schizoaffective Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Schizoaffective Disorder Market

• 14.1. South Korea Schizoaffective Disorder Market Overview
• 14.2. South Korea Schizoaffective Disorder Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Schizoaffective Disorder Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Schizoaffective Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Schizoaffective Disorder Market

• 15.1. Western Europe Schizoaffective Disorder Market Overview
• 15.2. Western Europe Schizoaffective Disorder Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Schizoaffective Disorder Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Schizoaffective Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Schizoaffective Disorder Market

• 16.1. UK Schizoaffective Disorder Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Schizoaffective Disorder Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Schizoaffective Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Schizoaffective Disorder Market

• 17.1. Germany Schizoaffective Disorder Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Schizoaffective Disorder Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Schizoaffective Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Schizoaffective Disorder Market

• 18.1. France Schizoaffective Disorder Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Schizoaffective Disorder Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Schizoaffective Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Schizoaffective Disorder Market

• 19.1. Italy Schizoaffective Disorder Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Schizoaffective Disorder Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Schizoaffective Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Schizoaffective Disorder Market

• 20.1. Spain Schizoaffective Disorder Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Schizoaffective Disorder Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Schizoaffective Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Schizoaffective Disorder Market

• 21.1. Eastern Europe Schizoaffective Disorder Market Overview
• 21.2. Eastern Europe Schizoaffective Disorder Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Schizoaffective Disorder Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Schizoaffective Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Schizoaffective Disorder Market

• 22.1. Russia Schizoaffective Disorder Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Schizoaffective Disorder Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Schizoaffective Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Schizoaffective Disorder Market

• 23.1. North America Schizoaffective Disorder Market Overview
• 23.2. North America Schizoaffective Disorder Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Schizoaffective Disorder Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Schizoaffective Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Schizoaffective Disorder Market

• 24.1. USA Schizoaffective Disorder Market Overview
• 24.2. USA Schizoaffective Disorder Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Schizoaffective Disorder Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Schizoaffective Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Schizoaffective Disorder Market

• 25.1. Canada Schizoaffective Disorder Market Overview
• 25.2. Canada Schizoaffective Disorder Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Schizoaffective Disorder Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Schizoaffective Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Schizoaffective Disorder Market

• 26.1. South America Schizoaffective Disorder Market Overview
• 26.2. South America Schizoaffective Disorder Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Schizoaffective Disorder Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Schizoaffective Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Schizoaffective Disorder Market

• 27.1. Brazil Schizoaffective Disorder Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Schizoaffective Disorder Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Schizoaffective Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Schizoaffective Disorder Market

• 28.1. Middle East Schizoaffective Disorder Market Overview
• 28.2. Middle East Schizoaffective Disorder Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Schizoaffective Disorder Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Schizoaffective Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Schizoaffective Disorder Market

• 29.1. Africa Schizoaffective Disorder Market Overview
• 29.2. Africa Schizoaffective Disorder Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Schizoaffective Disorder Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Schizoaffective Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Schizoaffective Disorder Market Competitive Landscape And Company Profiles

• 30.1. Schizoaffective Disorder Market Competitive Landscape
• 30.2. Schizoaffective Disorder Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis

31. Schizoaffective Disorder Market Other Major And Innovative Companies

• 31.1. Takeda Pharmaceutical Company Limited
• 31.2. Eli Lilly and Company
• 31.3. Boehringer Ingelheim International GmbH
• 31.4. Zydus Lifesciences Limited
• 31.5. Neurocrine Biosciences Inc.
• 31.6. Alkermes Inc.
• 31.7. Luye Pharma Group Ltd.
• 31.8. Merz Pharma GmbH & Co. KGaA
• 31.9. Acadia Pharmaceuticals Inc.
• 31.10. Intra-Cellular Therapies Inc.
• 31.11. Cerevel Therapeutics Inc.
• 31.12. Avanir Pharmaceuticals Inc.
• 31.13. Otsuka Pharmaceutical Co. Ltd.
• 31.14. Reviva Pharmaceuticals Inc.
• 31.15. Zogenix Inc.

32. Global Schizoaffective Disorder Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Schizoaffective Disorder Market

34. Recent Developments In The Schizoaffective Disorder Market

35. Schizoaffective Disorder Market High Potential Countries, Segments and Strategies

• 35.1 Schizoaffective Disorder Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Schizoaffective Disorder Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Schizoaffective Disorder Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer